Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Deubiquitinase Usp9X Regulates Cell Survival and Metabolic Signal Transduction in Multiple Myeloma Cells

Luke F. Peterson, PhD, Hanshi Sun, PhD, Vaibhav Kapuria, Ph.D., Malathi Kandarpa, PhD, Moshe Talpaz, MD, Andrzej J Jakubowiak, MD, PhD, Nicholas Donato, PhD

Blood (2011) 118 (21): 1835.

https://doi.org/10.1182/blood.V118.21.1835.1835

Published: 2011

Journal Articles

Mechanism of Action of a Small Molecule Inhibitor That Targets Usp9x Deubiquitinase Activity in Multiple Myeloma and Mantle Cell Lymphoma

Luke F. Peterson, PhD, Hanshi Sun, PhD, Matthew Young, PhD, Hollis D. Showalter, Ph.D., Andrzej J Jakubowiak, MD, PhD, Moshe Talpaz, MD, Nicholas Donato, PhD

Blood (2011) 118 (21): 1415.

https://doi.org/10.1182/blood.V118.21.1415.1415

Published: 2011

Journal Articles

The Novel BCR-ABL1 V304D Mutation Induces Pan-Tyrosine Kinase Inhibitor Resistance by a Unique Kinase Lateral Escape Mechanism and Is Associated with Very Poor Prognosis In Patients (PTS) with Chronic Myeloid Leukemia (CML).

Sabrina Pricl, PhD, Don L Gibbons, MD, PhD, Paola Posocco, PhD, Erik Laurini, PhD, Maurizio Fermeglia, Hagop M. Kantarjian, MD, Moshe Talpaz, MD, Jorge Cortes, MD, Matthew Young, PhD, Hanshi Sun, PhD, Luke F. Peterson, PhD, Nicholas Donato, PhD, Alfonso Quintás-Cardama, MD

Blood (2010) 116 (21): 3402.

https://doi.org/10.1182/blood.V116.21.3402.3402

Published: 2010

Journal Articles

In Silico modelling of Sensitivity to Novel Tyrosine Kinase Inhibitors of Highly Resistant Single and Polymutant BCR-ABL1 .

Sabrina Pricl, PhD, Don L Gibbons, MD, PhD, Paola Posocco, PhD, Erik Laurini, PhD, Maurizio Fermaglia, PhD, Hagop M. Kantarjian, MD, Moshe Talpaz, MD, Jorge Cortes, MD, Nicholas Donato, PhD, Alfonso Quintás-Cardama, MD

Blood (2010) 116 (21): 3388.

https://doi.org/10.1182/blood.V116.21.3388.3388

Published: 2010

Journal Articles

Inhibition of Usp9x Deubiquitinase Activity by WP1130 Reduces Mcl-1 Levels and Induces Apoptosis In Cells From Patients with Plasma Cell Dyscrasia and Drug-Refractory Multiple Myeloma

Hanshi Sun, PhD, Vaibhav Kapuria, Ph.D., Luke F. Peterson, PhD, Diane Giannola, Kandarpa Malathi, Ph.D., Moshe Talpaz, MD, Andrzej J Jakubowiak, MD, PhD, Nicholas Donato, PhD

Blood (2010) 116 (21): 3005.

https://doi.org/10.1182/blood.V116.21.3005.3005

Published: 2010

Journal Articles

Wnt-Pathway Directed Compound Targets Blast Crisis and Chronic Phase CML Leukemia Stem Progenitors.

Luke F Peterson, PhD, Anjanette J Turbiak, PhD, Diane M Giannola, BSc, Nicholas Donato, Hollis H.D. Showalter, PhD, Eric R Fearon, MD, PhD, Moshe Talpaz, MD

Blood (2009) 114 (22): 2168.

https://doi.org/10.1182/blood.V114.22.2168.2168

Published: 2009

Journal Articles

Degrasyn (a novel tyrophostin) Impacts BCR-ABL Protein Level and Is Cytotoxic to Chronic Myeloid Leukemia Early Progenitors

Luke F Peterson, PhD, Hanshi Sun, PhD, William Bornmann, PhD, Zhenghong Peng, PhD, David Maxwell, PhD, Nicholas Donato, Moshe Talpaz

Blood (2008) 112 (11): 3212.

https://doi.org/10.1182/blood.V112.11.3212.3212

Published: 2008

Journal Articles

Targeting Autophagy Potentiates Imatinib-Induced Cell Death in Philadelphia Positive Cells Including Primary CML Stem Cells.

Blood (2008) 112 (11): 1070.

https://doi.org/10.1182/blood.V112.11.1070.1070

Published: 2008

Journal Articles

WP-1130 Induces Apoptosis in Multiple Myeloma Cells by Inactivation of Jak2 and Syk Tyrosine Kinases Via a Novel Mechanism of Selective Protein Trafficking

Daniel Lebovic, Vaibhav Kapuria, Malathi Hari, Moshe Talpaz, Andrzej Jakubowiak, Nicholas Donato

Blood (2008) 112 (11): 2661.

https://doi.org/10.1182/blood.V112.11.2661.2661

Published: 2008

Journal Articles

Mutational Analysis of Chronic Phase Chronic Myeloid Leukemia (CMLCP) Clones Reveals Heightened BCR-ABL1 Genetic Instability in Patients Failing Sequential Imatinib and Dasatinib Therapy.

Alfonso QuintasCardama, MD, Don L. Gibbons, M.D., Ph.D., Hagop M. Kantarjian, MD, Moshe Talpaz, Nicholas Donato, PhD, Jorge Cortes, MD

Blood (2008) 112 (11): 2114.

https://doi.org/10.1182/blood.V112.11.2114.2114

Published: 2008

Journal Articles

Degrasyn-Induced Trafficking of BCR-ABL as a Novel Mechanism of Kinase Inactivation.

Nicholas Donato, PhD, Vaibhav Kapuria, MS, Hanshi Sun, PhD, David Maxwell, PhD, Geoffrey Bartholomeusz, PhD, William Bornmann, PhD, Zhenghong Peng, PhD, Ashutosh Pal, PhD, Moshe Talpaz, MD

Blood (2007) 110 (11): 1003.

https://doi.org/10.1182/blood.V110.11.1003.1003

Published: 2007

Journal Articles

Sequencing of Subcloned PCR Products Facilitates Earlier Detection of BCR-ABL1 T315I Mutants Compared to Direct Sequencing of the ABL1 Kinase Domain.

Alfonso Quintás-Cardama, MD, Don L. Gibbons, M.D., Ph.D., Hagop Kantarjian, M.D., Moshe Talpaz, M.D., Nicholas Donato, Ph.D., Jorge Cortes, M.D.

Blood (2007) 110 (11): 1952.

https://doi.org/10.1182/blood.V110.11.1952.1952

Published: 2007

Journal Articles

Dasatinib Resistance in CML Patients. Identification of Novel BCR-ABL Kinase Domain Mutation.

Yelena Krijanovski, MD, Nicholas Donato, PhD, Alfonso Quintas-Cardama, MD, Jorge Cortes, MD, Moshe Talpaz, MD

Blood (2007) 110 (11): 1957.

https://doi.org/10.1182/blood.V110.11.1957.1957

Published: 2007

Journal Articles

Mutations within BCR-ABL1 295–312 Define a Novel Region Associated with Poor Prognosis in Patients with Chronic Myelogenous Leukemia (CML) Resistant to Imatinib.

Alfonso Quintás-Cardama, MD, Don L. Gibbons, M.D., Ph.D., Hagop Kantarjian, M.D., Moshe Talpaz, M.D., Jorge Cortes, M.D., Nicholas Donato, Ph.D.

Blood (2007) 110 (11): 1936.

https://doi.org/10.1182/blood.V110.11.1936.1936

Published: 2007

Journal Articles

A Novel Small-Molecule Approach To Inhibit Jak2 Tyrosine Kinase Signaling.

Vaibhav Kapuria, MS, Geoffrey Bartholomeusz, PhD, Ling-Yuan Kong, PhD, William Bornmann, PhD, Zhenghong Peng, PhD, Ashutosh Pal, PhD, David Maxwell, PhD, Moshe Talpaz, MD, Nicholas Donato, PhD

Blood (2007) 110 (11): 1556.

https://doi.org/10.1182/blood.V110.11.1556.1556

Published: 2007

Journal Articles

A Novel BCR-ABL Mutation Predicts Resistance to Tyrosine Kinase Inhibitor (TKI) Therapy by a Unique Mechanism in Patients (pts) with Philadelphia-Positive (Ph+) Leukemia.

Alfonso Quintas-Cardama, MD, Jorge Cortes, MD, Hagop M. Kantarjian, MD, Moshe Talpaz, MD, Ji Wu, Feng Meng, Nicholas Donato, PhD

Blood (2006) 108 (11): 4773.

https://doi.org/10.1182/blood.V108.11.4773.4773

Published: 2006

Journal Articles

Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance

Joya Chandra, Jeannette Tracy, David Loegering, Karen Flatten, Srdan Verstovsek, Miloslav Beran, Mercedes Gorre, Zeev Estrov, Nicholas Donato, Moshe Talpaz, Charles Sawyers, Kapil Bhalla, Judith Karp, Edward Sausville, Scott H. Kaufmann

Blood (2006) 107 (6): 2501–2506.

https://doi.org/10.1182/blood-2005-07-2966

Published: 2006

Journal Articles

Hematologic and Cytogenetic Responses in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study.

Charles L. Sawyers, Neil P. Shah, Hagop M. Kantarjian, Nicholas Donato, John Nicoll, Stephen A. Bai, Fei Huang, Edwin Clark, Arthur P. DeCillis, Moshe Talpaz

Blood (2004) 104 (11): 1.

https://doi.org/10.1182/blood.V104.11.1.1

Published: 2004

Journal Articles

Hematologic and Cytogenetic Responses in Imatinib-Resistant Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study.

Moshe Talpaz, Hagop Kantarjian, Neil P. Shah, Nicholas Donato, John Nicoll, Stephen A. Bai, Fei Huang, Edwin Clark, Arthur P. DeCillis, Charles Sawyers

Blood (2004) 104 (11): 20.

https://doi.org/10.1182/blood.V104.11.20.20

Published: 2004

Journal Articles

Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor–κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis

Alok C. Bharti, Nicholas Donato, Sujay Singh, Bharat B. Aggarwal

Blood (2003) 101 (3): 1053–1062.

https://doi.org/10.1182/blood-2002-05-1320

Published: 2003

NARROW

Deubiquitinase Usp9X Regulates Cell Survival and Metabolic Signal Transduction in Multiple Myeloma Cells

Mechanism of Action of a Small Molecule Inhibitor That Targets Usp9x Deubiquitinase Activity in Multiple Myeloma and Mantle Cell Lymphoma

The Novel BCR-ABL1 V304D Mutation Induces Pan-Tyrosine Kinase Inhibitor Resistance by a Unique Kinase Lateral Escape Mechanism and Is Associated with Very Poor Prognosis In Patients (PTS) with Chronic Myeloid Leukemia (CML).

In Silico modelling of Sensitivity to Novel Tyrosine Kinase Inhibitors of Highly Resistant Single and Polymutant BCR-ABL1 .

Inhibition of Usp9x Deubiquitinase Activity by WP1130 Reduces Mcl-1 Levels and Induces Apoptosis In Cells From Patients with Plasma Cell Dyscrasia and Drug-Refractory Multiple Myeloma

Wnt-Pathway Directed Compound Targets Blast Crisis and Chronic Phase CML Leukemia Stem Progenitors.

Degrasyn (a novel tyrophostin) Impacts BCR-ABL Protein Level and Is Cytotoxic to Chronic Myeloid Leukemia Early Progenitors

Targeting Autophagy Potentiates Imatinib-Induced Cell Death in Philadelphia Positive Cells Including Primary CML Stem Cells.

WP-1130 Induces Apoptosis in Multiple Myeloma Cells by Inactivation of Jak2 and Syk Tyrosine Kinases Via a Novel Mechanism of Selective Protein Trafficking

Mutational Analysis of Chronic Phase Chronic Myeloid Leukemia (CMLCP) Clones Reveals Heightened BCR-ABL1 Genetic Instability in Patients Failing Sequential Imatinib and Dasatinib Therapy.

Degrasyn-Induced Trafficking of BCR-ABL as a Novel Mechanism of Kinase Inactivation.

Sequencing of Subcloned PCR Products Facilitates Earlier Detection of BCR-ABL1 T315I Mutants Compared to Direct Sequencing of the ABL1 Kinase Domain.

Dasatinib Resistance in CML Patients. Identification of Novel BCR-ABL Kinase Domain Mutation.

Mutations within BCR-ABL1 295–312 Define a Novel Region Associated with Poor Prognosis in Patients with Chronic Myelogenous Leukemia (CML) Resistant to Imatinib.

A Novel Small-Molecule Approach To Inhibit Jak2 Tyrosine Kinase Signaling.

A Novel BCR-ABL Mutation Predicts Resistance to Tyrosine Kinase Inhibitor (TKI) Therapy by a Unique Mechanism in Patients (pts) with Philadelphia-Positive (Ph+) Leukemia.

Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance

Hematologic and Cytogenetic Responses in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study.

Hematologic and Cytogenetic Responses in Imatinib-Resistant Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study.

Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor–κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only